The DOI matches its Crossref record.
Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy.
Abstract
PURPOSE: To evaluate the effect of granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) on bone marrow glucose metabolism in rodents and in patients, as assessed by 2-[fluorine-18]-fluoro-2-deoxy-D-glucose (FDG) uptake measured directly or by positron-emission tomography (PET) scanning. MATERIALS AND METHODS: Groups of three rats received either daily saline, G-CSF, or GM-CSF injections for 7 days. After treatment, FDG was injected and F-18 activities in tissues measured 1 hour later. Twenty-two breast cancer patients treated with multiagent chemotherapy were sequentially studied with PET. Eleven patients received G-CSF therapy as an adjunct to chemotherapy, while 11 received chemotherapy only. The standardized uptake value-lean (SUL) of bone marrow FDG uptake was measured and compared. RESULTS: In rats, bone marrow F-18 activity was significantly higher in both CSF groups than in the saline group (G-CSF, 0.44 +/- 0.08; GM-CSF, 0.33 +/- 0.02; saline, 0.18 +/- 0.02% injected dose [ID]/g x kg; P < .05), but the other normal tissues had comparable biodistributions to controls. In breast cancer patients, the FDG uptake of bone marrow did not change with chemotherapy alone; however, marrow uptake was increased after treatment with G-CSF. The dose of G-CSF and duration of treatment were correlated with the extent of increase in FDG uptake. The SUL of bone marrow was as follows: baseline, 1.56 +/- 0.23; after one cycle, 3.13 +/- 1.40 (P < .01); after two cycles, 2.22 +/- 0.85 (P < .05); and after three cycles, 2.14 +/- 0.79 (P < .05), respectively. Although the FDG uptake of bone marrow declined after G-CSF treatment was completed, it was higher than the baseline level for up to 4 weeks postcompletion of G-CSF and the elevated marrow FDG uptake was sustained longer than the period of blood neutrophil count elevation. CONCLUSION: Substantial increases in bone marrow FDG uptake are rapidly induced by CSF treatments and should not be misinterpreted as diffuse bone marrow metastases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pitfalls in Oncologic Diagnosis with FDG PET Imaging: Physiologic and Benign Variants
Shreve, P. D., Anzai, Y., & Wahl, R. L. (1999) · RadioGraphics · doi:10.1148/radiographics.19.1.g99ja0761 · Cited by 827
Self-citationBone Imaging in Metastatic Breast Cancer
Hamaoka, T., Madewell, J. E., Podoloff, D. A., Hortobagyi, G. N., & Ueno, N. T. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.181 · Cited by 656
False-Positive FDG PET Uptake−the Role of PET/CT
Rosenbaum, S. J., Lind, T., Antoch, G., & Bockisch, A. (2006) · European Radiology · doi:10.1007/s00330-005-0088-y · Cited by 315
The role of FDG-PET scans in patients with lymphoma
Seam, P., Juweid, M. E., & Cheson, B. D. (2007) · Blood · doi:10.1182/blood-2007-06-097238 · Cited by 304
Clinical role of positron emission tomography in oncology
Bomanji, J., Costa, D., & Ell, P. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(00)00257-6 · Cited by 281
Metadata
- Authors
- Sugawara, Y., Fisher, S. J., Zasadny, K. R., Kison, P. V., Baker, L. H., & Wahl, R. L.
- Venue
- Journal of Clinical Oncology
- Published
- 1998-01
- Volume
- 16
- Issue
- 1
- Pages
- 173-180
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1955188776
- Cited by
- 199
- References
- 0
- FWCI
- 0.98
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. https://app.cochat.ai/papers/10.1200/jco.1998.16.1.173
- The paper
- Sugawara, Y., Fisher, S. J., Zasadny, K. R., Kison, P. V., Baker, L. H., & Wahl, R. L. (1998). Preclinical and clinical studies of bone marrow uptake of fluorine-1-fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1998.16.1.173
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.